Format: Symposium

1-5 of 5 Activities
Title
Availability
Format
Credits
Launch Date
Buttons
Live
Symposium
1.5
10/09/2025 at 11:45 AM EDT

The MEKtrix: Advancing Neurofibromatosis Type 1 Care Across the Lifespan

In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management.

1.5
10/09/2025 at 11:45 AM EDT

Lionel Chow, MD, PhD

Lionel Chow, MD, PhD

Rebecca Brown, MD, PhD

Rebecca Brown, MD, PhD

Moderator

Livestream: The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

In this CE Concepts livestream symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

1.5
09/14/2025 at 3:30 PM EDT

Carlos Romo, MD

Carlos Romo, MD

Miriam Bornhorst, MD

Miriam Bornhorst, MD

Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Moderator

The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

1.5
09/14/2025 at 3:30 PM EDT

Carlos Romo, MD

Carlos Romo, MD

Miriam Bornhorst, MD

Miriam Bornhorst, MD

Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Moderator

Live
Symposium
1
09/27/2025 at 12:00 PM EDT

Livestream: MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

In this CEC Oncology livestream, case-based symposium, expert faculty will discuss key characteristics of clinical presentation and disease advancement over a lifespan; review patient and caregiver education needs on the integration of MEK inhibitors in the management of NF1-associated PNs; and explore the role of nurses in comprehensive care plans, including disease monitoring, treatment personalization, toxicity management, and transitioning care of patients with NF1 across their lifespan.

1
09/27/2025 at 12:00 PM EDT

Sanita Burgic, MSN, APRN, AGNP-C

Sanita Burgic, MSN, APRN, AGNP-C

AeRang Kim, MD, PhD

AeRang Kim, MD, PhD

Amy Armstrong, MD

Amy Armstrong, MD

Live
Symposium
1
09/27/2025 at 12:00 PM EDT

MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

In this CEC Oncology live, case-based symposium, expert faculty will discuss key characteristics of clinical presentation and disease advancement over a lifespan; review patient and caregiver education needs on the integration of MEK inhibitors in the management of NF1-associated PNs; and explore the role of nurses in comprehensive care plans, including disease monitoring, treatment personalization, toxicity management, and transitioning care of patients with NF1 across their lifespan.

1
09/27/2025 at 12:00 PM EDT

Sanita Burgic, MSN, APRN, AGNP-C

Sanita Burgic, MSN, APRN, AGNP-C

AeRang Kim, MD, PhD

AeRang Kim, MD, PhD

Amy Armstrong, MD

Amy Armstrong, MD